Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals adds Ted Love to board; Kenneth O'Keefe to retire December 1

Neutral Impact 2 of 5 leadership Written later

Jazz Pharmaceuticals said its board appointed Dr. Ted Love as a director effective December 1, 2025, and he will join the Audit and Science and Medicine committees. Director Kenneth W. O'Keefe will retire from the board on the same date, and the filing says his decision was not due to any dispute with the company. The change is a routine board update that does not include financial results or guidance.

Key points

  • Dr. Ted Love appointed to the board effective December 1, 2025, as a Class I director with a term expiring at the 2027 annual meeting
  • Dr. Love joins the Audit Committee and Science and Medicine Committee
  • Kenneth W. O'Keefe will retire from the board effective December 1, 2025; the filing says no dispute or disagreement led to his decision
  • Board decision on Love appointment dated October 23, 2025; filing dated October 28, 2025

The filing

CompanyJazz Pharmaceuticals (JAZZ)
Form8-K, current report
Filed with the SECOct 28, 2025, 4:15 PM ET
Accession number0001628280-25-046763

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:11 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.